Status:
COMPLETED
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
Lead Sponsor:
Novartis
Conditions:
Chronic Myelogenous Leukemia in Chronic Phase
Eligibility:
All Genders
15-74 years
Phase:
PHASE3
Brief Summary
This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.
Eligibility Criteria
Inclusion
- Diagnosed as Chronic Myelogenous Leukemia in Chronic Phase
- Previously untreated with Interferon-alpha
- Performance status is normal or capable of only limited self-care
Exclusion
- Patients who are pregnant or possibly pregnant
- Significant hepatic diseases
- Chronic Myelogenous Leukemia in advanced phase
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00237120
Start Date
November 1 2002
End Date
June 1 2007
Last Update
November 23 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.